After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Yahoo Finance discussed the stock recently as it posted Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Arcutis Biotherapeutics Inc is $1.06B. A total of 2.75 million shares were traded on the day, compared to an average of 6.23M shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, ARQT has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 14 BUYs and 11 SELLs from insiders. Insiders purchased 198,338 shares during that period but sold 26,364.
In the most recent transaction, Watanabe Todd Franklin sold 2,465 shares of ARQT for 10.60 per share on Feb 28. After the transaction, the insider now owns 889,436 company shares. In a previous transaction on Jan 02, Burnett Patrick sold 1,325 shares at 3.54 per share. ARQT shares that the insider owns now total 57,032.
Among the insiders who sold shares, Matsuda Masaru disposed of 1,850 shares on Nov 21 at a per-share price of $1.98. This resulted in the See Remark holding 46,634 shares of ARQT after the transaction. In another insider transaction, Frazier Life Sciences VIII, L. bought 80,000 shares at $2.50 per share on Oct 24. Company shares held by the 10% Owner now total 8,764,232.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ARQT has a high of $15.47 and a low of $1.76.
As of this writing, ARQT has an earnings estimate of -$0.74 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.65 per share and a lower estimate of -$0.91. The company reported an EPS of -$0.73 in the last quarter, which was 15.10% higher than expectations of -$0.86.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ARQT’s latest balance sheet shows that the firm has $387.06M in Cash & Short Term Investments as of fiscal 2021. There were $77.56M in debt and $33.33M in liabilities at the time. Its Book Value Per Share was $0.92, while its Total Shareholder’s Equity was $297.68M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARQT is Buy with a score of 4.50.
